

# MEDA

2009 annual report

FILED 10/20/09



## Contents





2	Milestones	106	Proposed allocation of profits
3	2009 in figures	107	Audit report
4	CEO's report	108	Financial review
7	Trends and specialty pharma	110	Corporate governance report
12	Strategy and business development	114	Definitions
14	Agreements, partnerships, and key events	116	Risk factors
17	Meda in brief	119	The Meda share
23	Sales and marketing	122	Board of directors
26	Product portfolio	124	Senior executives
37	Drug development	126	Product overview
41	Manufacturing	128	Glossary
43	Meda's responsibilities	129	Shareholder information
52	Management report		
59	Consolidated accounts		
63	Group notes		
91	Parent company accounts		
96	Parent company notes		

## Milestones

- Integration of Valeant's European pharmaceutical operations completed.
- FDA approval and launch on the US market of Astepro once-daily, the first single-dose nasal antihistamine, and Onsolis, for treatment of break-through pain in cancer patients.
- Progress for Retigabine (treatment of epilepsy). New drug applications submitted to FDA and EMEA and approved for further evaluation.
- New strategic partnerships:
  - In-licensing of exclusive rights to Xerese (cold sores) in North America.
  - In-licensing of exclusive rights to Ceplene (maintenance treatment and relapse prevention in patients with acute myeloid leukemia) in Australia, China, Europe, and Japan.
  - Extended commercialization rights for:
    - \* Onsolis (breakthrough pain in cancer patients)
    - \* Combination product azelastine and fluticasone (allergic rhinitis)
    - \* Axorid (rheumatic disorders)
  - Expanded product portfolio in dermatology via new license agreements with Valeant for two acne treatment products.

## 2009 in figures

- Group sales reached SEK 13,178 million (10,675).
- EBITDA rose to SEK 4,387 million (3,425).
- Operating profit rose to SEK 2,902 million (2,302).
- Profit after tax rose to SEK 1,537 million (954).
- Earnings per share increased to SEK 5.09 (3.49).
- Proposed dividend per share: SEK 1.00 (0.75).



\*) Including restructuring costs of SEK 215 million in 2008 and SEK 131 million in 2009.

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.